Theravance Biopharma and Mylan Submit NDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Nov. 13, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ( " Theravance Biopharma " ) and Mylan N.V. (NASDAQ, TASE: MYL) ( " Mylan " ) today announced the submission of a New Drug Application...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news